Table 1.
Composition of the experimental M. hyopneumoniae bacterins and their route of administration.
| Vaccine formulation | Dose (mL) | Delivery system | Immune-stimulators (μg/dose) | Antigen dose (CCU) | Administration route | |
|---|---|---|---|---|---|---|
| Primo | Booster | |||||
| Lipo_AMP | 2 | DPPC:DC-Chol liposomes | C-di.AMP (100) | 109 | IM | IM |
| Lipo_TLR | 2 | DPPC:DC-Chol liposomes | Pam3Cys-SK4/CpG ODN SL03/resiquimod (80/80/80) | 109 | IM | IM |
| PLGA_TLR | 2 | PLGA micro-particles (combined to ethylaminoethyl-dextran) | Pam3Cys-SK4/CpG ODN SL03/resiquimod (80/80/80) | 109 | IM | IM |
| SWE_TLR | 2 | squalene-in-water emulsion | Pam3Cys-SK4/CpG ODN SL03/resiquimod (80/80/80) | 109 | IM | IM |
| Lipo_DDA:TDB | IM 2 ID 0.2 | DDA liposomes | TDB (500) | IM 109 ID 2x108 | IM+ID | IM |
CCU, color changing units; IM, intramuscular; ID, intradermal; DPPC:DC-Chol, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine and dimethylaminoethane-carbamoyl-cholesterol; c-di-AMP, bis-(3′,5′)-cyclic dimeric adenosine monophosphate; PLGA, poly(lactic-co-glycolic acid); DDA, dimethyl dioctadecylammonium; TDB, trehalose 6,6′-dibehenate.